

IPSEN UNITED KINGDOM

European Federation of Pharmaceutical Industries and Associations (EFPIA) TRANSPARENCY
PROGRAM

METHODOLOGICAL NOTE

Summarising the methodologies used by IPSEN in preparing the disclosures and identifying Transfers of Value (ToVs) to Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) in accordance with ABPI and EFPIA Code of Practice requirements, Ipsen Group considerations, and local considerations due to locally applicable laws and regulations.

The report covers the disclosure of ToVs from 1 January 2025 to 31 December 2025

United Kingdom

Contents

Introduction.....	4
Terminology.....	4
1 DEFINITIONS	5
1.1 Recipients.....	5
1.1.1 Healthcare professional	5
1.1.2 Healthcare Organisation	5
1.2 Kind of ToVs.....	6
1.2.1 Donations and grants	6
1.2.2 Collaborative Working including Joint Working	6
1.2.3 Contribution to costs of events.....	7
1.2.4 Contracted Service Fees and Expenses	8
1.2.5 Research and Development (R&D):.....	9
2 DISCLOSURE’S SCOPE	10
2.1 Products concerned.....	10
2.2 Company concerned.....	11
2.3 Excluded Transfers of value.....	11
2.3.1 Hospitality costs.....	11
2.3.2 Specific consideration: Market Research.....	11
2.3.3 Specific consideration: Third parties’ interaction.....	12
2.4 Transfers of Value Date	13
2.5 Direct Transfers of Value	14
2.6 Indirect Transfers of Value.....	14
2.7 Non-monetary Transfers of Value	14
2.8 Transfers of Value in case of partial attendances or cancellation and refund..	14
2.9 Cross-border activities.....	15
2.10 R&D	15
2.11 Voluntary Disclosure.....	15
3 SPECIFIC CONSIDERATIONS	15
3.1 Country Unique Identifier	15
3.2 Self-incorporated HCP	15
3.3 Multi-year Agreements	16
3.4 Country Specificities	16
3.5 Quality Checks.....	16



United Kingdom

- 4 Data protection legal basis 16
 - 4.1 Consent collection 17
 - 4.2 Legitimate Interests..... 17
 - 4.2.1 The legitimate interests 17
 - 4.2.2 Necessity of processing 17
 - 4.2.3 Balance of interests 18
 - 4.2.4 Right to Object 19
- 5 Form of disclosure..... 19
 - 5.1 Date of Publication 19
 - 5.2 Disclosure Platform 20
 - 5.3 Disclosure Language 20
- 6 Disclosure Financial Data 20
 - 6.1 Currency 20
 - 6.2 VAT Included or Excluded 20
 - 6.3 Calculation rules 21
- 7 Additional Information 21
 - 7.1 Dispute management 21

INTRODUCTION

Collaboration between the pharmaceutical industry and HCPs and HCOs benefits patients. It is a relationship that has delivered new medicines and fosters the innovation that improves patients' lives. Ipsen is fully committed to complying with the codes and guidelines EFPIA and its member associations (the ABPI in the United Kingdom) have adopted to ensure that these interactions meet the high standards of integrity that patients, society, governments and other stakeholders expect.

Bringing greater transparency to this already well-regulated and vital relationship, builds understanding of industry and HCP/HCO collaboration and, in the context of increasing societal expectations on transparency, addresses directly public concerns about interactions between the medical community and the pharmaceutical industry.

Therefore, Ipsen documents and discloses all ToVs it makes, directly or indirectly, to or for the benefit of an HCP/HCO recipient.

Ipsen, like EFPIA and ABPI members, recognises that:

- Collaborative working between HCPs/HCOs and commercial life sciences organisations has long been a positive driver for advancements in patient care and the progression of innovative medicine.
- This also plays a big part in informing the pharmaceutical industry's efforts to improve patient care and treatment options – and is essential in improving health outcomes. A healthy working relationship between the pharmaceutical industry and HCPs/HCOs is in the best interest of patients.

Therefore, based on the EFPIA and ABPI Codes of Practice, Ipsen:

- Across Europe, from 30 June 2016, is fully committed to ensure transparency is respected, resulting in being open about our activities and interactions by disclosing payments made to HCP/HCOs as described in the EFPIA and ABPI Codes of Practice.

TERMINOLOGY

Standard abbreviations or terms are presented in the table below.

ACRONYMS AND ABBREVIATIONS	
CRO	Clinical Research Organisation
EFPIA	European Federation of Pharmaceutical Industries and Associations
HCO	Healthcare Organisation
HCP	Healthcare Professional
OTC	Medicines which can be delivered without prescription and never reimbursed
PCO	Professional Congress Organiser

United Kingdom

PO	Patient Organisation
POM	Prescription Only Medicine (Rx)
ToV	Transfer of Value
UK	United Kingdom

1 DEFINITIONS

1.1 Recipients

1.1.1 Healthcare professional

As a general principle, Ipsen considers that disclosure must be made on the contracting entity. Ipsen fully follows the ABPI and EFPIA definitions.

ABPI definition: the ABPI Code “applies to the promotion of medicines to members of the United Kingdom health professions and to other relevant decision makers.” The term ‘Health Professional’ includes “members of the medical, dental, pharmacy and nursing professions and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.” The term ‘Other Relevant Decision Makers’ particularly includes “someone with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who is not a health professional.”

EFPIA definition: “any natural person that is a member of the medical, dental, pharmacy or nursing professions or any other person who, in the course of his/her professional activities, may prescribe, purchase, supply, recommend or administer a Medicinal Product and whose primary practice, principal professional address or place of incorporation is in Europe. For the purpose of this Code, the definition of HCPs includes: (i) any official or employee of a government, agency or other organisation (whether in the public or private sector) that may prescribe, purchase, supply, recommend or administer Medicinal Products and (ii) any employee of a Member Company whose primary occupation is that of a practising HCP, but excludes (x) all other employees of a Member Company and (y) a wholesaler or distributor of medicinal Products.”

1.1.2 Healthcare Organisation

As general principle, Ipsen considers that disclosure must be made on the contracting entity. Ipsen fully follows the ABPI and EFPIA definitions.

ABPI definition: “either a healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university or other teaching institution or learned society whose business address, place of incorporation or primary place of operation is in Europe or an organisation through which one or more health professionals or other relevant decision makers provide services.”

EFPIA definition: “any legal person/entity (i) that is a healthcare, medical or scientific association or organisation (irrespective of the legal or organisational form) such as a hospital, clinic, foundation, university or other teaching institution or learned society (except

for Patient Organisations (POs) within the scope of article 21) whose business address, place of incorporation or primary place of operation is in Europe or (ii) through which one or more HCPs provide services.”

POs are not considered to be HCOs and are separately included in the PO report displayed on Ipsen website.

1.2 Kind of ToVs

1.2.1 Donations and grants

Ipsen discloses ToVs related to donations and grants, which is a payment made to a third party without consideration or any kind of return in exchange of such payment for an **educational, scientific or a charitable** purpose:

- An **Educational Grant** is funding provided to medical association or a PO to support an independent medical education program; Scholarships, Fellowships; Awards.
- A **Research Grant** is funding to third-party registered research entities to conduct independent research that does not fall under the definition of company sponsored studies or Investigator-sponsored studies under the applicable Ipsen R&D policies.
- A **donation** is a charitable contribution to a non-profit third-party entity (charities) with charitable and philanthropic intent, without any expressed or implied benefit other than general goodwill.

ABPI: *“collectively mean providing funds, benefits-in-kind or services freely given for the purpose of supporting healthcare, scientific research or education, with no consequent obligation on the recipient organisation, institution and the like to provide goods or services to the benefit of the pharmaceutical company in return. Donations and grants to individuals are prohibited.*

In general, donations are physical items, services or benefits-in-kind which may be offered or requested. Grants are the provision of funds.”

EFPIA: *“Section 12.01. Donations and Grants (in cash or in kind or otherwise) to HCOs and/or POs are only allowed if: (i) they are made for the purpose of supporting healthcare, research or education; (ii) they are documented and kept on record by the donor/grantor; and (iii) they do not constitute an inducement to recommend and/or prescribe, purchase, supply, sell or administer specific Medicinal Products.”*

1.2.2 Collaborative Working including Joint Working

Collaborative Working which either enhances patient care or is for the benefit of patients or alternatively benefits the NHS and, as a minimum, maintains patient care is acceptable providing it is carried out in a manner compatible with the ABPI Code. Collaborative Working is generally between one or more pharmaceutical companies, healthcare organisations and other organisations. Joint Working is a form of Collaborative Working.

United Kingdom

All ToV relating to Collaborative Working including Joint Working in the United Kingdom (UK) are captured in the Disclosure report. In general, where Ipsen has made a financial or non-financial contribution to a Joint or Collaborative Working project then such contribution will be disclosed in the year in which the payment was made.

The executive summaries of these Collaborative Working Agreements can be accessed via the links provided in the Disclosure report. These executive summaries are also available on Ipsen's website - www.ipsen.com/uk-ireland/.

1.2.3 Contribution to costs of events

Ipsen discloses ToVs related to events at an individual level, i.e., at HCP or HCO level in line with the Codes.

The ToVs disclosed under this section relate to either:

- a) Third-party organised events - organised by an independent third party, such as a learned society, HCP association etc. An international scientific congress is an example of third-party events.
 - **HCP Sponsorship:** Ipsen may sponsor HCPs to attend congresses or events to enhance their medical and/or scientific knowledge, and their use of medicines. In this context, the sponsorship covers **congress registration, travel, accommodation** and meals. The HCP does not receive any compensation, as no service is provided from the HCP (see *categories 1. and 3. below*).
 - **Congress Sponsorship:** Ipsen may also **sponsor a third-party event** (congress for example), in exchange for services such as a slot for an Ipsen satellite symposium (educational activity independently organised by Ipsen and held within the congress, the admission of employees to the congress) or a booth (see *category 2. below*). The ToVs related to sponsorships are always made to an organisation.
- b) Ipsen standalone meetings - these are events initiated by Ipsen to provide information on an Ipsen medicinal product, therapeutic area, treatment options, etc. or as a response to address a legitimate need for scientific information. Hospitality can be provided to HCPs that participate in such meetings. Logistical costs, i.e., travel and accommodation, are disclosed, however not room rental or potential equipment.

In both cases, the hospitality levels are governed by local rules (resulting from local transposition of the EFPIA Code of Practice setting amount thresholds for hospitalities).

The report section "*Contribution to costs of events*" is composed of three categories:

- 1 **Registration fees:** participants' admission fees to third-party events are included in sponsorship of HCPs.
- 2 **Sponsorship agreements:** as outlined in Article 23.05 of the EFPIA Code of Practice, with HCOs or third parties (such as professional congress organisers (PCOs)) appointed by HCOs to manage an event. In the latter case, the sponsorship is considered as an indirect ToV to an HCO. Examples of ToV disclosed include rental of booth space, satellite symposia slot at a congress

United Kingdom

(Ipsen controlled event at third-party event). In all cases, ToVs are disclosed against the HCO that ultimately benefits.

- 3 Travel and accommodation:** provided to HCPs as part of HCP sponsorships at third-party events or related to HCP participation at Ipsen stand-alone meetings. Examples of ToV disclosed include flight tickets, train tickets, taxi, hotel accommodation. For mass group transport (e.g., a bus / coach) organised for an event, the cost is allocated to each individual HCP having benefited from the travel.

Refer to Part 8.3 for detailed calculation rules.

EFPIA: *“Contribution to costs related to Events, through HCOs or third parties, including sponsorship to HCPs to attend Events, must be disclosed individually under the name of the Recipient: such costs may relate to: Registration fees; Sponsorship agreements with HCOs or with third parties appointed by an HCO to manage an Event; and Travel and accommodation (to the extent governed by Article 10 of the EFPIA HCP Code). Since 30 June 2016, companies disclose transfers of value made to HCPs, such as consultancy and advisory boards, speaker fees, and sponsorship to attend meetings. This transformational step in the relationship between industry and health professionals is a result of the EFPIA Disclosure Requirements. (EFPIA FAQ Question 3).”*

Additional notes for Sponsorships:

ABPI: Clause 28.3 states *“Payments to healthcare organisations are required to be disclosed on a per activity basis.”* Each payment amount for Registration Fees or Travel & Accommodation paid to an HCO will therefore be disclosed on an individual basis under “Contribution to costs related to Events”, rather than a Total Amount paid in a given year as stated in the EFPIA Code.

EFPIA: *“Contributions provided to Events through PCOs – that would therefore be the Recipient of the ToVs – must be considered as indirect ToVs. When a Member Company contributes to the costs related to Events through PCOs, the following reporting approaches are considered compliant with EFPIA reporting requirements:*

All ToVs to an HCO (either as Recipient or as Beneficiary) are reported in the relevant category under the name of the HCO and ToVs through PCOs are reported:

- *either in the name of benefitting HCO (through include the name of Recipient PCO), if not included in direct ToVs to the HCO.*
- *or in the name of Recipient PCO (to the benefit of include the name of benefitting HCO).”*

1.2.4 Contracted Service Fees and Expenses

Ipsen may contract with an HCP or HCO in exchange for services provided by the HCP or HCO based on scientific/medical expertise, reputation, knowledge and experience in a particular therapeutic area. Ipsen enters contractual arrangements with an HCP or an HCO only where there is a legitimate business or scientific need which cannot be satisfied by internal or other available sources. The services provided are insights, presentations or other consulting services.

United Kingdom

Participation in consultancy agreements requires an investment of time and expertise from the HCP, over and above their principal practice. Therefore, it is appropriate that they are paid for their time and reimbursed for expenses such as travel. Remuneration must be part of a written agreement, be strictly related and proportional to the services rendered, be in line with fair market value and comply with relevant Code of Practice, regulations and laws.

In this section Ipsen discloses services at individual level, i.e., at HCP or HCO level, the fees and related expenses, in two separate ToV categories:

- 1 **Fees:** fees for services to HCPs/HCOs. Examples include speaker fees, fees for insights provided during an Advisory Board¹, fees for consultancy.

- 2 **Related expenses:** Where a service agreement is in place, other expenses may occur which do not constitute part of the fees but relate to the provision of this service and are reimbursed to the HCP/HCO. Such ToVs are disclosed in this category. Examples include taxi fares.

EFPIA: *“ToVs resulting from or related to contracts between Member Companies and HCOs under which such HCOs provide any type of services to a Member Company, or any other type of funding not covered in the previous categories. Fees, on the one hand, and on the other hand ToVs relating to expenses agreed in the written agreement covering the activity will be disclosed as two separate amounts.”*

1.2.5 Research and Development (R&D):

Ipsen will disclose ToV to HCPs or HCOs as per the Codes; related to the planning or conduct of:

- Non-clinical studies
- Clinical trials
- Non-interventional studies - that are prospective in nature and that involve the collection of patient data from or on behalf of individual, or groups of, HCPs specifically for the study

Definitions:

Non-clinical studies (Source: *OECD Principles on Good Laboratory Practice*): Non-clinical health and environmental safety study, henceforth referred to simply as "study", means an experiment or set of experiments in which a test item is examined under laboratory conditions or in the environment to obtain data on its properties and/or its safety, intended for submission to appropriate regulatory authorities.

1 An **Advisory Board** is a group of external experts convened by a company to get their professional advice and insights on a specific topic for which the expertise and knowledge are not available within the company. Advisors (experts in their areas) can be HCPs, payers, patients, representatives of patient associations, patient advisors and non-HCP specialists, e.g., Market Access specialists. Covering scientific and / or healthcare-related issues, Advisory Boards help us to better understand the external environment, therapeutic area, data and use of products approved or in development, clinical and medical asset strategies, or unmet medical needs.

United Kingdom

Clinical trials (*Source: OECD Principles on Good Laboratory Practice*): Any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmaco-dynamic effects of one or more investigational medicinal product(s), and/or to identify any adverse reactions to one or more investigational medicinal product(s) and/or to study absorption, distribution, metabolism and excretion of one or more investigational medicinal product(s) with the object of ascertaining its (their) safety and/or efficacy.

Non-interventional studies (*Source: OECD Principles on Good Laboratory Practice*): Studies where the medicinal product(s) is (are) prescribed in the usual manner in accordance with the terms of the marketing authorisation. The assignment of the patient to a particular therapeutic strategy is not decided in advance by a trial protocol but falls within current practice and the prescription of the medicine is clearly separated from the decision to include the patient in the study. No additional diagnostic or monitoring procedures shall be applied to the patients and epidemiological methods shall be used for the analysis of collected data.

Examples of R&D ToV that are disclosed in this section (if the related study falls into the EFPIA definition of R&D):

- Collaboration Agreement
- Clinical Study Agreement
- Consulting Agreement - Services Agreement
- Speaker Agreement
- Advisory Board
- Investigator meeting
- Ancillary services patient care
- Ethics committee fees

EFPIA: *“Payments made for research and development activities are disclosed in aggregate. For the purposes of the disclosure, these activities are defined as transfers of value to HCPs or HCOs related to the planning or conduct of:*

- *non-clinical studies (as defined in OECD Principles on Good Laboratory Practice).*
- *clinical trials (as defined in Directive 2001/20/EC); or*
- *non-interventional studies (NIS) that are prospective in nature and that involve the collection of patient data from or on behalf of individual, or groups of, HCPs specifically for the study (Section 18.01 of the EFPIA Code).*

Transfers of Value relating to NIS that are not within the definition of R&D ToVs under the EFPIA Disclosure Code must be reported on an individually named basis. For sake of clarity, activities not falling within the definition of R&D ToVs, including NIS that are not conducted to maintain a marketing authorization (in application and following definitions of the “Clinical Trials” Regulation 536/2014), will be disclosed under “consultancy/fee-for-services”.

2 DISCLOSURE’S SCOPE

2.1 Products concerned

Ipsen will collect, report and disclose all ToVs to HCPs/HCOs in relation to prescription-only medicines as described within the Code.

United Kingdom

ABPI: the ABPI Code “does not apply to the promotion of over-the-counter medicines to members of the health professions when the object of that promotion is to encourage their purchase by members of the public.” ToV related to OTC products will not be disclosed in the UK.

2.2 Company concerned

The report covers the disclosure of ToVs to HCOs or HCPs that practice or are registered in the UK that are performed by Ipsen, its affiliates and acquired or merged companies irrespective of their location.

2.3 Excluded Transfers of value

2.3.1 Hospitality costs

As general principle, Ipsen fully follows EFPIA rules related to ToV excluded from the scope. As stated in Part 3.2.2, the hospitality levels are governed by local rules (resulting from local transposition of the EFPIA Code of Practice setting amount thresholds for hospitality).

ABPI: Clause 10.8 states “The cost of any subsistence (food and drink) provided must not exceed £75 per person, excluding VAT and gratuities.” Furthermore, in the supplementary information to Clause 10.8 “The maximum of £75 plus VAT and gratuities (or local equivalent) does not apply when a meeting is held outside the UK in a European country where the national association is a member of EFPIA and thus covered by EFPIA Codes. In such circumstances the limits in the host country code would apply. Information can be found at www.efpia.eu.”

EFPIA: Excluded Disclosures. “Without limitation, ToVs that; ... (ii) are not listed in Section 23.05 of this article, such as Items of Medical Utility 29 (governed by Article 17), meals (governed by Article 10, especially Section 10.05), Medical Samples (governed by Article 19); or (iii) are part of ordinary course purchases and sales of Medicinal Products by and between a Member Company and a HCP (such as a pharmacist) or a HCO do not fall within the scope of the disclosure obligation described above in “General Obligation”. Meals and drinks are not disclosed, but a threshold has been applied in each country, limiting hospitality under a certain value. The Code does not require to be disclosed: inexpensive items of medical value; information and educational materials designed for patients; samples; and activities solely relating to over-the-counter medicines. [Q&A – Q7]”

As per the EFPIA Code, hospitality costs are not disclosable if in line with the limits set within the national association following Art 10 of the HCP Code (in alignment with the ABPI Code). Ipsen applies these limits for Ipsen-organised and sponsored meetings, and therefore costs of meals & drinks are excluded. However, where meals and drinks make up an integral and inseparable part of contributions to the cost of events or sponsoring as part of sponsorship agreements with HCOs, they have been included in the ToV disclosed.

2.3.2 Specific consideration: Market Research

Market research is the process of gathering and analysing information related to a specific market, in a systematic and objective manner. The purpose of any market research project is to achieve an increased understanding of the subject matter. Most of the time, market research is covered

United Kingdom

by contracting arrangements between Ipsen and external vendors; personal information of respondents is then kept fully confidential by the vendor.

In case of ToV related to market research, three situations can occur:

- If the names of the respondent HCPs are not known, the ToV is not disclosed.
- If the names of the HCPs are known and they have not objected to disclosure, the ToV is disclosed at individual level.
- If the names of the HCPs are known and they have objected to individual disclosure and that objection is agreed, the ToV is disclosed at aggregate level.

In line with EFPIA Code.

EFPIA: *“The Member Company knows the identity of the HCP/HCO participating in activities defined as market research the Member Company should disclose it in the “Fees for Service and Consultancy” category. Section 15.04. Limited market research, such as one-off phone interviews or mail/e-mail/ internet questionnaires are excluded from the scope of this Article 15, provided that the HCP, HCO’s member or PO’s Representative is not consulted in a recurring manner (either with respect to the frequency of calls generally or of calls relating to the same research) and that the remuneration is minimal.”*

2.3.3 **Specific consideration: Third parties’ interaction**


In some parts of the world, Ipsen operates through partners and distributors. Therefore, Ipsen considers that if the Partner is a member of EFPIA, or a member of the local association member of EFPIA in the country of the HCP/HCO, and/or if the country where the Partner operates has adopted a legislation providing for transparency of interactions between the pharmaceutical industry and HCPs and HCOs, the Partner is responsible for documenting and disclosing ToV made to HCPs and HCOs, in accordance with the local code of conduct or legislation, and in compliance with applicable personal data law protection.

When the partner is not a member of EFPIA or when the recipient comes from a country where the partner is not a member of the local association member of EFPIA, two cases can occur:

- The partner discloses on a voluntary basis or through contractual obligations: These ToV are then excluded from the Ipsen Transparency reports.
- The partner does not disclose: Ipsen discloses only the ToV linked to activities included in the scope of EFPIA, made on behalf of Ipsen, and when final recipients / costs are known by Ipsen. In these cases, the partner commits to assist Ipsen in fulfilling its obligations under the Code by collecting the required information and consents, where applicable, for the processing and disclosure of the relevant ToV to HCPs and HCOs.

The following figure summarises the approach followed.

Third parties interactions



EFPIA: “Third parties provide support to Member Companies in a variety of capacities, impacting more or less on the conduct of activities regulated by the EFPIA Codes. Such activities would be reported as indirect ToVs following provisions of the EFPIA Disclosure Code. When Member Companies provide support / sponsorship to PCOs involved in the organisation of scientific Events, it is understood that the Member Companies’ intention is to provide support to

HCPs/HCOs at arm’s length. Indirect ToVs are those made on behalf of a Member Company for the benefit of a Recipient, or ToVs through an intermediate and where the Member Company knows or can identify the HCP/ HCO that will benefit from the ToV.”

2.4 Transfers of Value Date

For **direct ToV linked to an event:**

- When the information is collected from the financial system (direct payments): Date of the payment
- When the information is manually collected: Date of the event (or the 1st day of a congress)

For **direct ToV not linked to an event** (fees for consultancy for example):

- Date of the invoice reception or date of the payment

For **indirect ToV linked to an event:**

- Date of the event (or the 1st day of an event)

For **indirect ToV not linked to an event** (fees for consultancy for example):

- Date of the invoice reception or date of the payment

However, different rules apply for specific cases:

- For ToV related to the Clinical Operations department (non –interventional studies, Phase II, III, IV trials), the issue date of the invoice is considered.

United Kingdom

In the case of multi-year contract, the date of the payment is considered. If several payments occur within several reporting periods, each disclosure will contain payments done during the appropriate reporting period.

2.5 Direct Transfers of Value

Direct ToV are payments made directly by Ipsen for the benefit of a Recipient.

ABPI definition: “a direct or indirect transfer of value, whether in cash, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development or sale of medicines. A direct transfer of value is one made directly by a company for the benefit of a recipient.”

The natural or legal person that holds the bank account on which the money is transferred is considered the recipient of the ToV and will be disclosed. The exception to this is that if an HCP has directed that payment under a fee for services contract should be paid to a company where that HCP is the sole shareholder then the ToV will be recorded against that HCP and not the company.

2.6 Indirect Transfers of Value

Indirect transfers of value are payments made by a third party (such as contractors, Clinical Research Organisations (CROs), agents, partners, affiliates (including foundations)) on behalf of Ipsen for the benefit of a Recipient, where the identity of Ipsen is known or can be identified by the Recipient that will benefit from the ToV.

ABPI definition: “An indirect transfer of value is one made on behalf of a company for the benefit of a recipient or through an intermediate and where the company knows or can identify the recipient that will benefit from the transfer of value.”

Third parties, such as agencies organising meeting arrangements on Ipsen’s behalf, have been trained on the ABPI Code of Practice disclosure requirements and provide Ipsen with a detailed tracker of the ToV made to HCPs and HCOs.

2.7 Non-monetary Transfers of Value

For any significant non-monetary ToV a monetary value shall be assigned in line with applicable local market pricing, understood as the amount a private party should generally have to pay to acquire a unit of a good, product, material, article, etc.

2.8 Transfers of Value in case of partial attendances or cancellation and refund

Ipsen shall disclose effective ToV. In relation to contribution to costs of an event, when an HCP fails to attend a meeting they were supposed to, no cost is disclosed under the name of the “no-shows”.

2.9 Cross-border activities

At Ipsen, a “cross-border” activity is defined as an activity initiated either by an Ipsen affiliate with a Recipient coming from one or several countries, or by a Corporate department. To comply with the EFPIA and ABPI Codes which require disclosure in the country where the recipient has its principal practice (HCP) or where it is registered (HCO), whether the ToV occurs in or outside of that country, the cross-border activities management process has been refined in order to capture all expenses from any Ipsen entity to HCPs/HCOs within the scope of EFPIA and ABPI requirements.

The Disclosure report for the UK includes all disclosable ToV made by Ipsen Limited and by any of our affiliates or Corporate department.

2.10 R&D

Ancillary services provided in hospitals (i.e., hospital services provided by non-medical staff) can be related to patient care provided during a trial, or can be non-patient related (e.g., data building). The latter is often outsourced to specialised organisations. Ancillary services directly related to patient care in a trial fall within the scope of the Code and are therefore disclosed on an aggregate basis. Ancillary services that are not directly related to patient care in a trial are considered business-to-business transactions that are not subject to the Code’s disclosure requirements.

A CRO is not considered as an HCO. Therefore, the fees paid to CROs for the services they provide to Ipsen are not included in the scope of the disclosure. However, the indirect ToV through CROs that ultimately benefit HCPs/HCOs are disclosed in R&D section. The contracts with the CROs have been adapted to include provisions related to the CROs’ obligation to provide Ipsen with detailed information related to indirect ToV that benefit HCP/HCO.

2.11 Voluntary Disclosure

Not applicable.

3 SPECIFIC CONSIDERATIONS

3.1 Country Unique Identifier

The disclosure template includes a unique country identifier as a field of mandatory filling for each HCP and HCO. For each ToV Ipsen must be able to identify the Recipient. To this end, a unique identifier is assigned for each Recipient.

3.2 Self-incorporated HCP

As general principle, Ipsen considers that disclosure must be made on the contracting entity. However, where an HCP has set up their own company (where they are the only employee of the corporation), and Ipsen has made a payment to that company for services provided by the HCP, ToVs have been disclosed against the individual HCP.

United Kingdom

Where an organisation is principally made up of a group of HCPs, but where the ToV cannot be reasonably ascribed to an individual HCP within the organisation, this organisation has been designated an HCO and the ToV disclosed accordingly.

3.3 Multi-year Agreements

As indicated in section 4.4 Transfer of Value Date, in the case of multi-year contracts, the date of the payment is considered. If several payments occur within several reporting periods, each disclosure will contain payments done during the appropriate reporting period.

3.4 Country Specificities

All ToV relating to Collaborative Working including Joint Working in the UK are captured in the Disclosure report. In general, where Ipsen has made a financial or non-financial contribution to a Joint or Collaborative Working project then such contribution will be disclosed in the year in which the payment was made.

The executive summaries of these Collaborative Working Agreements can be accessed via the links provided in the Disclosure report. These executive summaries are also available on Ipsen's website - www.ipsen.com/uk-ireland/.

3.5 Quality Checks

Ipsen uses a combination of automated systems, standardised procedures and manual data entry through internal and external resources to collect relevant information and its subsequent publication. The information published reflects our good faith and best efforts to comply with the provisions of the EFPIA and ABPI Codes. If, despite Ipsen's best efforts to ensure a publication that accurately reflects the ToV performed, Ipsen failed to include correct and complete information, Ipsen will investigate and provide an appropriate response if the information is incorrect.

4 DATA PROTECTION LEGAL BASIS

The collection and use of personal data are subject to the UK Data Protection Act ([Data protection: The Data Protection Act - GOV.UK \(www.gov.uk\)](http://www.gov.uk)) and the European General Data Protection Regulation (GDPR) 2016/679. This applies to processing personal data about individual HCPs in the context of disclosing ToV information. When processing this data Ipsen ensures that personal data is handled in line the relevant principles and obligations, including transparency, data minimisation, accuracy, security, individual rights and lawfulness. We also ensure that any transfers of personal data from the EU to a third country outside of the EEA or to a country without an adequacy decision is subject to adequate safeguards, and approved contract terms, such as the EU standard contract clauses.

The legal basis (under Article 6 GDPR) for processing individual disclosure of ToV information linked to individual HCPs, varies by country. The legal basis in the UK is legitimate interests.

United Kingdom

All HCPs whose data will be disclosed, are provided with information about how their personal data is managed by Ipsen and on what legal basis it will be disclosed, along with information about their individual rights and how to exercise those rights.

The HCPs have the right to access their personal data, and they can object to individual disclosure. All HCPs have the right to seek correction of mistakes or inaccuracies in their personal data, regardless of the legal basis.

EFPIA: *When deciding how a ToV must be disclosed, Member Companies should, wherever possible, identify and publish at the individual HCP (rather than HCO) level, if this can be achieved with accuracy, consistency and in compliance with applicable laws and regulations.*

4.1 Consent collection

Not applicable.

4.2 Legitimate Interests

In the UK, HCPs are provided with a Privacy Notice as part of their contract detailing legitimate interest as the legal basis for the public disclosure of a ToV from Ipsen to an HCP on an individual basis. There is no requirement in the UK for Ipsen to obtain consent from an HCO to publicly disclose a ToV from Ipsen to an HCO on an individual basis.

Ipsen has considered the balancing test related to legitimate interests, where this applies. This is summarised below.

4.2.1 *The legitimate interests*

The objective of ToV disclosure is to protect the integrity of relationships with HCPs and HCOs and this is an important aspect of fostering greater transparency and building greater trust between the pharmaceutical industry, the medical community and society across Europe. The legitimate interests for disclosing ToV relate to several parties, as follows:

- Ipsen's legitimate interests in meeting the requirements of the EFPIA and ABPI Codes of Practice, which requires that each member company documents and discloses all ToVs it makes, directly or indirectly, to or for the benefit of HCPs, to protect the integrity of these relationships, foster greater transparency and build trust in the industry.
- The legitimate interest of local disclosure organisations to receive the data for publication, to help meet the overall objectives of ToV.
- The legitimate interests of HCPs, patients and the public, meeting a growing expectation that interactions between corporations and society are not only conducted with integrity but are also transparent, thus increasing trust.

4.2.2 *Necessity of processing*

The aim of TOV disclosure is to inform the public through transparency, so that every patient can be informed of the relationship between their HCP and the pharmaceutical sector and can

United Kingdom

take decisions based on this information. To achieve this, the information must be made public and should be linked to individually identified HCP, wherever possible. There are no less intrusive ways to achieve this objective.

4.2.3 *Balance of interests*

Nature of the data concerned:

- The personal data processed is limited to the minimum data required for the purpose. No “special category data” or data relating to criminal convictions, or data related to vulnerable data subjects is processed.
- The data relates to individuals in their professional rather than personal capacity and therefore generally carries less expectation of confidentiality or sensitivity.
- The ToV disclosure does not reveal the actual overall earnings of the HCPs and often represents a small fraction of the HCPs remuneration.
- ToV disclosure covers costs related to events (registration fees, travel and accommodation) and fees for service and consultancy agreements (fees and expenses). It does not include less relevant payments, such as for scientific research.

Reasonable expectations of the HCP:

ToV disclosures are in the reasonable expectations of the HCPs for the following reasons:

- HCPs are fully informed about ToV requirements when engaged by Ipsen.
- Disclosure requirements are well understood in the industry and have been in place since 2012.
- Individuals will already be aware through their professional bodies and place of work of the requirements and importance of transparency in the pharmaceutical industry.
- EPPIA has engaged with healthcare professional representative organisations on the issue and launched a social media platform to engage with individual HCPs. The practice of publishing ToV is thus very well known in the sector.

It is very unlikely that any HCP would not be aware of the publication of ToV.

Relationship between HCP and Ipsen:

Ipsen has a professional relationship with the HCPs. There is no imbalance of power between Ipsen and the HCP, and the HCPs do not have to enter into any contract, activity or agreement with Ipsen if they choose not to. HCPs are not deprived of any right with significant consequences if they refuse ToV.

What is the impact on individuals?:

United Kingdom

In principle, ToV disclosures are highly unlikely to result in any negative impact on the HCPs' individual rights and freedoms, and safeguards are included in the process to ensure this, including:

- Limiting information to the minimum required to meet the objectives and limiting ToV to relevant types of expenditure and activity, e.g. excluding scientific research.
- ToV information will only be publicly available for a period of 3 years, and there are protocols to avoid data on the internet being indexed by search engines, limiting the risk of unintended uses of the data.
- Ipsen is also bound to comply with data protection obligations whilst handling the personal data involved, including meeting individual rights, such as the right to object, when processing is based on legitimate interests.

4.2.4 *Right to Object*

Individuals retain the right to object to disclosure of their information and will retain their right to seek correction of mistakes or deletion of their information. If an individual objects, Ipsen will consider the reasons for the objection on a case-by-case basis and balance that with Ipsen's grounds to continue with the individual disclosure.

If they object to disclosure, the person responsible for collating the data for the activity will follow the process for managing objections.

All ToV will be disclosed on an individual basis unless the HCP objects to the individual disclosure and that objection is agreed, in which case, ToV must be disclosed in an aggregated way. If an individual objects to individual disclosure, this should not be to their disadvantage; Ipsen may continue working with them.

An objection from an HCP can be made in any form, e.g., it can be verbal or by email, and the objection can be made to anyone in Ipsen. When an HCP makes an objection Ipsen will review the reasons given and demonstrate that Ipsen has "compelling legitimate grounds" for the disclosing the data in identifiable form which overrides the individual's reasons for objecting or not. This involves carrying out a legitimate interest assessment for each objection. If the objection request is rejected, disclosure will be made on an individual basis. If the objection request is approved, disclosure will be made on an aggregate basis.

5 **FORM OF DISCLOSURE**

5.1 **Date of Publication**

30/06/26

Aligned with EFPIA and the ABPI, Ipsen discloses all the relevant ToVs by the 30th of June for the previous year according to the following situations:

The data will be in the public domain for 3 years and will be stored for minimum of 5 years. Ipsen will be able to modify or delete their disclosures at any time before or after the publication.

United Kingdom

ABPI: “Disclosures must be made annually in respect of each calendar year and must be in the first six months after the end of the calendar year in which the transfers of value/payments were made. The information disclosed must remain in the public domain for at least three years from the time of first disclosure. Companies must document all disclosures and retain the records for at least five years after the end of the calendar year to which they relate.”

EFPIA: “Disclosures must be made by each Member Company within 6 months after the end of the relevant Reporting Period and the information disclosed must be required to remain in the public domain for a minimum of 3 years after the time such information is first disclosed unless, in each case, (i) a shorter period is required under applicable national laws or regulations, or (ii) the relevant data protection legal basis (e.g. the legitimate interest grounds, a legal duty or the Recipient’s consent relating to a specific disclosure) is no longer applicable. The common reporting period for publication of ToVs to Recipients is set during the time interval from 20th to 30th June each year at the latest. Where a National Code provides a different time interval for its country, this must consistently apply to all disclosure obligations to Recipients.”

5.2 Disclosure Platform

Disclosure UK - www.disclosureuk.org.uk.

All the local reports disclosed by Ipsen are publicly available via the Corporate website: <https://www.ipсен.com/our-company-social-responsibility/>.

EFPIA: “Platform of Disclosure. Disclosures can be made in either of the following ways, provided that they are unrestricted and publicly available: on the relevant Member Company’s website in accordance with the section “Applicable National Code”; or on a central platform, such as one provided by the relevant government, regulatory or professional authority or body or a Member Association, provided that disclosures made on a central platform developed at the initiative of Member Associations must be made, so far as possible, using a structure set forth in Annex A for reference.”

5.3 Disclosure Language

English.

6 DISCLOSURE FINANCIAL DATA

6.1 Currency

GBP.

In the case where ToV have been made in a different currency, the Ipsen Transparency systems have calculated the disclosed amount in GBP, based on the daily exchange rate effective on the date of the ToV.

6.2 VAT Included or Excluded

Where possible, the Net amount is disclosed. If VAT cannot accurately be excluded, the Gross amount is disclosed.

United Kingdom

6.3 Calculation rules

General calculation including no-shows / cancellation fees and group expenses treatment:

- The costs of “no-shows” (occurring when an HCP fails to attend a meeting they were supposed to) - two situations can occur:
 - 1 Ipsen booked and paid in advance for a forecasted number of HCPs/HCOs:
 - Calculated Amount = (Actual cost / Forecasted number of attendees, including Ipsen staff and non-HCP attendees)
 - Disclosure: Calculated Amount, disclosed on actual attendees
 - *Example: Ipsen has paid in advance £100 for 8 HCPs and 2 Ipsen staff. Only 6 of the 8 HCPs have attended the meeting. For each of these 6 actual HCPs attendees, the calculated amount ($\frac{£100}{8+2} = £10$) is disclosed. No cost is disclosed under the name of the “no-shows”, nor on the Ipsen staff.*
 - 2 Ipsen paid fees according to the number of attendees:
 - Calculated Amount = (Actual cost / Actual number of attendees, including Ipsen staff and non-HCP attendees)
 - Disclosure: Calculated Amount, disclosed on actual attendees
 - *Example: A meeting is organized with 11 HCPs and 2 Ipsen staff. Only 8 of the 11 HCPs have attended the meeting. The final invoice paid by Ipsen for this meeting is £100. For each of the 8 actual HCPs attendees, the calculated amount ($\frac{£100}{8+2} = £10$) is disclosed. No cost is disclosed under the name of the “no-shows”, nor on the Ipsen staff.*
- Cancellation fees (penalty for annulling a confirmed arrangement or order) are not disclosed.

7 ADDITIONAL INFORMATION

7.1 Dispute management

Ipsen has implemented a responsive dispute process. Each question or claim is centralised and followed up. After a thorough analysis of the inquiry, all applicants will receive a response via a letter signed by Ipsen.

Objectives of the process are to:

- Answer to HCP/HCO claims and questions within a reasonable timeframe with respect to local regulation,
- Have an organised arbitration in case of litigation (Ipsen local Transparency Committee),
- Ensure an update of the Transparency report, taking into account legal constraint in less than 2 months.

United Kingdom

UK Dispute Management:

Individuals have the right to access, correct or object to publication of their personal data. Any disputes or queries will be managed as follows:

Pre-Disclosure:

If an HCP/HCO contacts Ipsen directly, they will be advised to log in to the ABPI Disclosure system (as detailed in the ABPI pre-disclosure letter) and raise their query on the pre-disclosure database. The ABPI's database partner will generate an email containing the HCP/HCO's contact details, details of the queried item(s) and any comments made by the HCP/HCO. This email will be sent to the Ipsen UK central Transparency email address (transparency.uk@ipsen.com) within two working days of receipt of the query.

Ipsen have 14 days to investigate the query and notify the ABPI of the outcome.

If required, the Disclosure UK database partner will then, within two working days, update its records, and the agreed figure will be published on the disclosure database. Disputed information will be updated in Ipsen's reporting tool if required and the ABPI Report will be updated and re-uploaded by Ipsen.

Post-Disclosure:

The pre-disclosure database will remain accessible to HCPs/HCOs once the Disclosure UK database goes live. If an HCP/HCO needs to raise a query after the database has gone live, they will be encouraged to do this on the pre-disclosure database using their individual login name and secure ID. This will ensure that each query is tracked from start to finish and to make sure that an individual's data privacy is not breached.

If an HCP/HCO is unwilling to use the pre-disclosure database, they will be advised to contact the ABPI using the following email address: info@disclosureuk.org.uk.

Once received, the ABPI will raise the query with the Disclosure UK database within two business days and follow the process outlined above.